Baseimmune data-driven vaccine design
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $17.17M
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | IQ Capital... | iqcapital.... |
| - | Creator Fu... | thecreator... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.03.2024 | Series A | $11.42M | - |
| 02.11.2021 | - | $4.8M | - |
| 01.04.2021 | - | $947.1K | - |
Mentions in press and media 11
| Date | Title | Description |
| 12.03.2026 | Baseimmune Announces Strategic Expansion into Fibrosis with Lead Program Targeting Idiopathic Pulmonary Fibrosis (IPF) | Baseimmune, a biotechnology company leveraging computational protein design to create next-generation immunotherapies, today unveiled its new fibrosis-focused pipeline, beginning with IPF. This press release features multimedia. View the fu... |
| 04.03.2024 | Baseimmune: £9 Million In Funding Raised To Predict Future Pathogen Mutations To Generate Novel Vaccines | Baseimmune – a biotech company that uses proprietary, deep learning AI to predict future pathogen mutations to generate novel vaccines – recently announced the closing of £9 million in Series A funding led by new investors MSD Global Health... |
| 01.03.2024 | Baseimmune: Revolutionizing Vaccine Development with AI | London-based Baseimmune, a biotech company, has secured €10.4M in funding to develop mutation-proof vaccines using AI. Led by MSD Global Health Innovation Fund and IQ Capital, the funding will accelerate the development of three vaccine can... |
| 01.03.2024 | StartUPDATES: New developments from healthcare startups | Alpha Sophia is set to make waves at the LSI USA 2024 Emerging MedTech Summit in Dana Point, California, from March 18-22. Led by CEO Paul-Lukas Hoffschmidt, Alpha Sophia will unveil a major product update during the event, promising signif... |
| 29.02.2024 | Baseimmune Closes £9M Series A Funding | Baseimmune, a London, UK-based biotech company that uses proprietary, deep learning AI to predict future pathogen mutations to generate novel vaccines, raised £9M in Series A funding. The round was led by MSD Global Health Innovation Fund a... |
| 27.02.2024 | UK-based Baseimmune raises €10.4M to develop mutation-proof vaccines using AI; here’s how | Read this article in: London-based Baseimmune, a biotech company using deep learning AI to forecast pathogen mutations for vaccine development, has secured $11.3M (approximately €10.40M) in a Series A round of funding. The round was led by ... |
| 02.11.2021 | London biotech Baseimmune closes £3.5M funding, eyes to develop future-proof universal vaccines | The COVID-19 pandemic has fuelled a renaissance in vaccine research, underpinned by the creation of novel vaccine delivery systems and robust worldwide manufacturing pipelines, with the global vaccine market predicted to reach $108 billion ... |
| 02.11.2021 | ‘Pick and mix’ technology promises future-proof universal vaccines against COVID and more | LONDON, UK - Imperial College-based biotech startup Baseimmune has secured $4.8m funding to develop the next generation of future-proof universal vaccines against major human and animal diseases. Baseimmune logo Around 1.5 million people di... |
| 01.04.2021 | Baseimmune raises €803K to create variant-proof COVID vaccines; backed by ex-Moderna exec, AstraZeneca vaccine co-inventor | In today’s scenario, there are a lot of factors involved in the emergence of new infectious diseases or the re-emergence of ‘old’ ones, with Covid-19 being the latest example. And according to Baseimmune – a biotech startup, the current est... |
| - | Baseimmune | “Baseimmune AI vaccine design” |
Show more